Thus, a treatment with the monoclonal antibody infliximab, an TNF-α antagonist, resulted in a greater reduction of depressive symptoms in a subset of medication resistant MDD patients with high baseline CRP levels (29). The gene discussed is CRP; the disease is major depressive disorder.